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Abstract: Diarrhea is the second leading cause of death among children less than 5 years of age. Most of these
deaths occur in developing countries in the tropical areas of Africa and South Asia. Goreisan/Wulingsan, a formula
of Japanese-Chinese medicinal herbs (Kampo), has been used for the treatment of diarrhea and vomiting from
ancient times in East Asia. Therefore, we planned a randomized controlled clinical trial of Goreisan/Wulingsan in
Bangladeshi children. Although it is believed to be safe in East Asia, information regarding its toxicity on animals
is scarce. Since Goreisan/Wulingsan has never been used in Bangladesh, it was necessary to ensure the safety of
the formula in an animal experiment. Rats were assigned to a control group (normal saline, n = 4) or various
Goreisan/Wulingsan groups (n = 26) receiving doses of 1 to 8 mg/g/day (7.7 to 61.5 times the recommended
pediatric dose) over a period of 25 days. Their activities and health conditions were observed until they were
sacrificed, after which blood samples were collected for biochemical liver function tests. The kidneys, liver and
heart tissue were collected for histopathological study. No lethality was observed during the experiment. All of the
rats consumed the doses completely and no constipation was observed, suggesting the absence of any inhibitory
effect on intestinal motion. Also, no abnormal neurological activity was detected, nor any significant elevation of
AST, ALT or ALP levels, except for AST and ALT at the highest dose of 8 mg/g/day. Histopathological studies of
the kidneys, liver and heart tissues revealed no abnormalities.
In conclusion, our results showed that Goreisan/Wulingsan is safe for rats, thereby justifying the use of the drug in
a human trial.
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INTRODUCTION
Acute diarrhea is the second leading cause of death
among children younger than 5 years of age, with 760,000
childhood deaths and 1.7 billion cases annually throughout
the world. Most of those deaths occur in developing coun-
tries in tropical areas of South Asia and Africa [1]. Acute
diarrhea is frequently complicated with vomiting. Viral
gastroenteritis, characterized by the acute onset of vomit-
ing and watery diarrhea, is the most frequent cause of diar-
rhea in children [2]. Therefore, acute gastroenteritis is a
serious health problem for children living in developing
countries, especially in tropical areas. Goreisan/Wulingsan
(called Goreisan in modern Japanese and Wulingsan in
modern Chinese using the original ancient Chinese charac-
ters) has been used for the treatment of acute watery diar-
rhea and vomiting for two thousand years in East Asia, i.e.
China, Korea, and Japan. It consists of five Japanese-
Chinese medicinal herbs, described later in the materials
and methods section. Goreisan/Wulingsan has been regar-
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ded since ancient time as a safe medicine. No severe ad-
verse effects of Goreisan/Wulingsan have been reporeted
since 1963 when the Japanese government approved the
clinical use of Goreisan/Wulingsan powder in its National
Health Insurance System [3]. The Goreisan/Wulingsan
used in the present study was in the form of Goreisanryo
extract granules (N-17) manufactured by Kotaro
Pharmaceutical Co., Ltd. A database of reported adverse
effects of Goreisanryo extract granules (N-17) from 1989
to 2007 shows only three cases involving mild adverse ef-
fects: two cases of abdominal pain and one case of exacer-
bated edema. All of these adverse effects promptly
improved on their own without additional care (informa-
tion from Kotaro Pharmaceutical Co., Ltd. Osaka, Japan).
However, the surveillance of adverse Goreisan/Wulingsan
effects has only been conducted in Japan. A Japanese man-
ufacturer of herbal medicine (Tsumura Co., Ltd, Tokyo,
Japan) reported a toxicological evaluation of their product,
Goreisan Extract Granules TJ-17, using a rat model [4].
However, the herbal components of their TJ-17 product are
a modified version of the original formulation of Goreisan/
Wulingsan. Modifed Goreisan (TJ-17) uses Atractylodis
Lanceae Rhizoma instead of Atractylodis Rhizoma. The
lethal single dose of modified Goreisan (TJ-17) has been
reported to be more than 12 mg/g. Repeated doses of 3
mg/g of modified Goreisan (TJ-17) over a one-month peri-
od did not induce any toxicological effect. Nevertheless,
information regarding the safety of original Goreisan/
Wulingsan in an animal model is scarce.
Recently, in an open label, controlled trial for children
with acute vomiting, Goreisan/Wulingsan proved to be
more effective at reducing vomiting than domperidone, a
dopamine antagonist [5]. With these results in mind, we
planned to undertake a randomized, double-blind, placebo
controlled, clinical trial (RCT) to evaluate the efficacy of
Goreisan/Wulingsan in reducing vomiting and diarrhea
among children with acute gastroenteritis. We decided to
conduct the RCT on children in Bangladesh (ISRCTN:
34440093), a country in South Asia where the morbidity
and mortality of acute gastroenteritis are high [6]. Howev-
er, the practice of using Goreisan/Wulingsan is new to
Bangladesh. Since most Bangladeshi (South Asian) people
belong to a different race than East Asian people, it is
speculated that the former might be genetically less toler-
ant to this medicine. However, no data or previous reports
are available to shed light on this issue.
Other than its curative effect on vomiting and diar-
rhea, Goreisan/Wulingsan is well known for its diuretic ef-
fect. Ahn et al. reported that the diuretic and natriuretic
effect of Goreisan/Wulingsan may be due to an inhibition
of the renin-angiotensin-aldosterone system [7]. Goreisan/
Wulingsan has also been reported to reduce renal stone for-
mation [8, 9]. Therefore, Goreisan/Wulingsan, which ex-
erts an effect on the kidney, may adversely affect kidney
function. Okada et al. reported that Goreisan/Wulingasn
decreased transaminase levels in mice fed highly fatty
foods and ethanol [10]. Since Goreisan/Wulingsan exerts
an effect on liver function, it may also adversely affect liv-
er function. As for modified Goreisan (TJ-17), liver dys-
function, although mild and rare, has been reported as an
adverse effect in humans. Accordingly, it was deemed im-
portant to ensure the safety of this traditional Japanese-
Chinese herbal medicine with an animal model before
starting a clinical trial. In this study, the toxicity of
Goreisan/Wulingsan was evaluated using a Long Evans rat
model.
MATERIALS AND METHODS
Dehydrated extract of Goreisan/Wulingsan
A dehydrated extract of Goreisan/Wulingsan, free of
all excipients, was kindly supplied by the Kotaro
Pharmaceutical Co., Ltd. (Osaka, Japan). A total of 3.2 g
of dehydrated Goreisan/Wulingsan was obtained from a
mixture of the following herbal medicines: Alismatis Rhi-
zoma (root of Alismaorientale Juzepczuk) 6.0 g, Atractylo-
dis Rhizoma (root of Atractylodes japonica Koidzumi ex
Kitamura) 4.5 g, Polyporus Sclerotium (body of Polyporu-
sumbellatus Fries) 4.5 g, Cinnamomi Cortex (bark of
Cinnamomum cassia Blume) 2.5 g, and Poria Sclerotium
(body of Poriacocos Wolf) 4.5 g. Cinnamic acid, Alisol A,
and Atractilenolide III are major ingredients of Cinnamomi
Cortex, Rhizoma Alismatis and Rhizoma Atractylodis, re-
spectively.
Animal study
Male and female Long Evans rats (with an average
weight of 165.25 g) were purchased from the Animal Re-
sources Branch of the International Centre for Diarrheal
Diseases and Research, Bangladesh (ICDDR,B). They
were fed the standard pellet diet provided by the ICDDR,B
and water ad libitum. The toxicity study was performed to
determine the safety limit of Goreisan/Wulingsan in Long
Evans rats and any adverse effects the drug might exert on
the kidney, liver and heart tissues of the animals. It was
conducted according to the Dhaka University’s Guidelines
for the Use of Laboratory Animals and Experiments and it
was approved by Dhaka University’s Ethical Committee
for Animal Experimentation.
Experimental design
The rats were assigned to a control group fed standard
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feed pellets and normal saline (n = 4), and Goreisan/
Wulingsan groups fed standard feed pellets and medicinal
doses of Goreisan/Wulingsan: 1 mg/g/day (n = 8); 2
mg/g/day (n = 6); 4 mg/g/day (n = 7); and 8 mg/g/day (n =
5). The rats received normal saline or different doses of
Goreisan/Wulingsan powder for 25 consecutive days. The
activity, appetite, and constipation of the rats were ob-
served visually and recorded.
Collection of blood samples
Blood samples were collected separately from the
throat vein of each rat after sacrificing the animals at the
end of the experiment. The blood samples were allowed to
clot at room temperature and then centrifuged at low speed
for 15 minutes. The separated serum from each rat was
stored at –20°C and brought to room temperature prior to
analysis.
Collection of tissue samples
Collected promptly after sacrificing the rats, the kid-
ney, liver and heart tissues were sliced into pieces of a few
millimeters in thickness, immersed in properly labeled
glass beakers containing 10% formaldehyde and then stor-
ed for three days.
Biochemical and histopathological analysis of the
samples
Biochemical liver function tests, i.e. measurement of
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), and alkaline phosphatase (ALP) in the serum of
the rats, were carried out in the Laboratory Medicine De-
partment at the Institute of Child and Mother Health
(ICMH). The biochemical analyses were carried out using
colorimetric spectrophotometry.
The kidney, liver and heart tissues collected from the
sacrificed rats were fixed in paraffin and sliced into 4
μm‑thick sections. Deparaffined and stained with
Hematoxylin-Eosin (H-E) stain, the sections were ob-
served under a light microscope at magnifications of 400×
and 1000× (histopathological examination) in the Depart-
ment of Pathology, Bangabandhu Sheikh Mujib Medical
University (BSMMU), Bangladesh.
Statistical analysis
Multiple comparisons of the means of liver function
markers in the control group and Goreisan/Wulingsan
groups were performed at each dose using a two-sided
Dunnett test with SPSS software (version 17.0; SPSS, Inc.,
Chicago, Illinois, USA). A p-value of less than 0.05 was
considered to be statistically significant.
RESULTS
Visual rat inspections and rat survival data
All of the rats in both the control group and Goreisan/
Wulingsan groups consumed their medication completely.
No abnormal habitation change or feeding activity was ob-
served in any of the rats over the 25-day study period, nor
did any of the rats suffer constipation. In addition, no ab-
normal movement, excitation or lethargy was observed
among the rats in the study group. Since all of the rats sur-
vived for the 25-day study period with an up to 8 mg/g
dose of Goreisan/Wulingsan, we were unable to establish a
lethal dose within this range.
Biochemical liver function tests using rat sera
The results of biochemical liver function tests are
shown in Fig. 1. The mean and SD of serum AST levels
(IU/L) in the control group and the rats fed 1, 2, 4, and 8
mg/g/day of Goreisan/Wulingsan were 43.8 ± 16.0, 34.9 ±
9.5, 45.3 ± 10.3, 46.1 ± 23.2, and 88.4 ± 21.6, respectively.
The mean and SD of serum ALT levels (IU/L) in the con-
trol group and the rats fed 1, 2, 4, and 8 mg/g/day of
Goreisan/Wulingsan were 29.3 ± 8.0, 18.6 ± 3.2, 27.5 ±
8.9, 26.1 ± 5.6, and 48.0 ± 7.5, respectively. No statistical-
ly significant elevation of AST or ALT levels was ob-
served between the control group and the various
Goreisan/Wulingsan groups, except at the highest dose of
8 mg/g/day (AST: p = 0.001, ALT: p < 0.001). The mean
and SD of serum ALP levels (IU/L) in the control group
and the rats fed 1, 2, 4, and 8 mg/g/day of Goreisan/
Wulingsan were 279.0 ± 58.9, 268.5 ± 16.5, 220.7 ± 89.5,
284.9 ± 71.5, and 347.8 ± 60.1, respectively. With respect
to ALP levels, no statistically significant difference was
observed between the control group and any of the
Goreisan/Wulingsan groups.
Histopathological examination of rat tissue
The photomicrographs of H-E stained histopathologi-
cal sections of kidney, liver and heart tissues are shown in
Fig. 2. No histopathological change was observed between
the control group and the Goreisan/Wulingsan groups in
any of the examined tissues at doses of 1 to 8 mg/g/day.
DISCUSSION
This is the first study to verify the safety of Goreisan/
Wulingsan using a rat model. The recommended pediatric
daily dose (0.25 g/kg/day) of commercially available
Goreisan/Wulingsan powder, including excipient
(Goreisanryo N17, Kotaro Pharmaceutical Co., Ltd.,
Osaka, Japan ) is equivalent to a dose of 0.13 g/kg/day
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(0.13 mg/g/day) of dehydrated extracts of the five herbs of
Goreisan/Wulingsan (without the excipient) used in this
experiment. Therefore, the doses of Goreisan/Wulingsan
used for this animal study were 7.7 to 61.5 times higher
than the recommended pediatric dose of Goreisan/
Wulingsan powder. All of our test rats survived and re-
mained healthy over the 25-day observation period, a re-
sult indicating that Goreisan/Wulingsan is also safe for use
in various human races worldwide.
All of our test rats consumed the medication and feed
pellets completely, and none of them suffered from consti-
pation. Therefore, Goreisan/Wulingsan displayed no major
inhibitory effect on intestinal movement, which should be
avoided in the treatment of infectious vomiting and diar-
Fig. 1. Plots of biochemical liver function tests. 
aspartateaminotransferase (AST); alanine amino-
transferase (ALT); and alkaline phosphatase (ALP).
These plots represent enzyme levels in the rats of the
control group and those of the Goreisan/Wulingsan
groups (at doses of 1, 2, 4 and 8 mg/g/day). 
The error bars indicate the standard deviations and the
dashed lines indicate the mean values for the data.
rhea. Although excitatory and inhibitory effects on the cen-
tral nervous system of mice have been reported at high
doses (more than 0.1 mg/g) of Cinnamaldehyde a chemical
component of Cinnamomumcassia Blume, one of the herbs
in Goreisan/Wulingsan [11], neither excitatory nor inhibi-
tory effects were observed in the central nervous system of
our test rats at doses of 1 to 8 mg/g/day. This also suggests
the likelihood that clinical doses of Goreisan/Wulingsan
cause no adverse effects on the central nervous system in
Fig. 2. Histopathological study of kidey, liver and heart
tissues collected from rats. 
Photomicrographs of Hematoxylin-Eosin (H-E)-
stained sections from the organs of rats belonging to
the control group and the Goreisan/Wulingsan group
at the highest Goreisan/Wulingsan dose of 8 mg/g/
day, as observed under a light microscope at 400 fold
magnification. A-1: kidney tissue from the control
group, A-2: kidney tissue from the Goreisan/
Wulingsan group at a dose of 8 mg/g/day. B-1: liver
tissue from the control group, B-2: liver tissue from
the Goreisan/Wulingsan group at a dose of 8 mg/g/
day. C-1: heart tissue from the control group, C-2:
heart tissue from the Goreisan/Wulingsan group at a
dose of 8 mg/g/day
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human subjects.
As for the serum liver function tests, we used human
liver function test kits since those for rats were not availa-
ble in Bangladesh. Therefore, the absolute liver function
test values that we obtained cannot be directly compared
with liver function test values in rats. However, a compari-
son of liver function test values among the Goreisan/
Wulingsan group with those of the control group might
still be useful for evaluating the effects on liver function.
With regard to AST and ALT levels, statistically signifi-
cant elevations of liver enzymes were only observed be-
tween the control group and the Goreisan/Wulingsan group
at the highest of the drug dose (8 mg/g/day). However, the
mean level of liver enzymes at the highest dose was, at
most, twice that of the control group, which is a clinically
acceptable variance. In addition, no abnormality was de-
tected in the histopathological studies of the liver tissue
from rats receiving Goreisan/Wulingsan, even at the high-
est dose.
Vomiting and diarrhea cause dehydration resulting in
decreased renal blood flow, and this could damage kidney
tissue and make it more susceptible to renal toxic agents.
Hence, renal toxic agents should be avoided in the treat-
ment of vomiting and diarrhea. No pathological change
was observed in the kidney tissues of rats fed Goreisan/
Wulingsan, at any dosage. Electrolyte imbalance, which is
induced by severe vomiting and diarrhea, can lead to occa-
sionally life-threatening arrhythmia, especially in patients
with underlying heart disease [12]. Therefore, any medi-
cine which is used to treat vomiting and diarrhea should be
tested for heart tissue toxicity. In our histopathological ex-
aminations of the rat heart tissue, we observed no adverse
change in the Goreisan/Wulingsan groups at any dosage.
Ahn et al. reported a diuretic effect of Goreisan/
Wulingsan [7]. If Goreisan/Wulingsan induced a diuretic
effect on children with dehydration, it would be very dan-
gerous because of the risk of kidney damage and electro-
lytic disorders. However, in another study, the urine
volume of rats fed Goreisan/Wulingsan was not signifi-
cantly different from that of control rats (rats fed normal
food) for 8 weeks [13]. The diuretic effect of Goreisan/
Wulingsan is therefore still controversial. Tei et al. repor-
ted that Goreisan/Wulingsan induced a remarkable diuretic
effect in mice loaded with excess water, even though it did
not induce a diuretic effect in mice with normal water in-
take. In addition, Goreisan/Wulingsan induced an anti-
diuretic effect in mice with dehydration [14]. Tashiro
reported a similar modulating effect of Goreisan/
Wulingsan on the water balance in a human subject [15].
Goreisan/Wulingsan induced a diuretic effect in a human
volunteer loaded with excess water but an anti-diuretic ef-
fect in a volunteer suffering from dehydration. Since
Goreisan/Wulingsan acts to normalize water balance, it is
suitable for the treatment of vomiting and diarrhea in pa-
tients with dehydration.
Regarding the limitations of our study, we did not as-
sess renal function or electrolytes using the rat serum.
Haranaka et al. reported that the creatinine clearance of
rats fed Goreisan/Wulingsan for 1 month was within a nor-
mal range [13]. Watabe et al. reported that concentrations
of potassium, sodium, calcium, magnesium, and chloride
in the sera of rats fed with Goreisan/Wulingsan for 1
month were similar to those in the control group [16]. As
for feeding activity, we only made visual observations.
Orita et al. reported that the amount of consumed food and
the body weight of rats fed Goreisan/Wulingsan for 8
weeks were not significantly different from those in the
control group (rats fed normal food) [17].
Our results can be summarized as follows. High doses
(7.7 to 61.5 times higher than the recommended pediatric
dose) of Goreisan/Wulingsan were given to rats. All the
animals survived and remained healthy over the 25-day
observation period. In addition, we observed no inhibition
of intestinal movement, no neurologically abnormal activi-
ty, no marked elevation of liver enzymes, and no patholog-
ical tissue change (kidney, liver and heart tissue). These
results indicate the safety of this Japanese-Chinese herbal
medicine in human patients suffering from vomiting and
diarrhea, a finding that may open the door for the use of
Goreisan/Wulingsan outside East Asia, especially in devel-
oping countries in tropical area of Africa and South Asia
where huge numbers of children die from acute gastroen-
teritis.
On the basis of our results, a clinical trial of Goreisan/
Wulingsan in Bangladeshi children with acute vomiting
and diarrhea was approved by the Ethical Committee of In-
stitute of Child and Mother Health, Dhaka, Bangladesh.
The trial was safely conducted between May 2008 and
May 2009 (manuscript under preparation). The efficacy of
Goreisan/Wulingsan on acute gastroenteritis (vomiting and
diarrhea) is promising from the view point of both our
clinical experience and an open label controlled study con-
ducted in Japan [5]. In a mice model, saline purgative-
induced diarrhea was reduced by Goreisan/Wulingsan
[18]. This finding suggests that Goreisan/Wulingsan mod-
ulates the water permeability of the intestinal membrane
and is effective in reducing secretory diarrhea. Since
Goreisan/Wulingsan is empirically effective for both vom-
iting and diarrhea, it is a promising candidate for adjunc-
tive therapy using oral rehydration salts (ORS). Vomiting
control makes ORS therapy successful, while diarrhea con-
trol prevents increases in the level of dehydration. In
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addition, the price of Goreisanryo N-17 (Kotaro
Pharmaceutical Co., Ltd.) is only 0.2 USD/day per child
with an 8 kg body weight. Since Goreisan/Wulingsan is af-
fordable in poor countries, it is expected to be a popular
choice for the control of diarrhea in children living in trop-
ical, developing countries.
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